Cryo-Save N.V. (Cryo-Save), the largest family stem cell bank in Europe, has acquired Salveo Biotechnology SA, the cord banking activities of Salveo Holding SA (Salveo), for an undisclosed consideration.
Cryo-Save is the leading international stem cell storage brand. It offers collection, analysis, processing and cryogenic preservation of stem cells obtained from the umbilical cord and from umbilical cord blood that can be used in medical therapies later in a child’s lifetime.
Salveo Biotechnology SA is the umbilical cord blood and umbilical cord tissue cryopreservation division of Salveo Holding SA, a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine.
Salveo Holding SA is a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine. Founded in 2011 and made up of experts in regenerative medicine, the group is also present in Italy, Spain, Portugal and Ukraine and has developed a dynamic and professional commercial network.
Salveo was selected to partner with Cryo-Save, acquiring all assets related to the distribution and commercial activities of Salveo's umbilical cord blood and umbilical cord tissue cryopreservation business. Frédéric Amar, CEO of Salveo, has also joined the board of Cryo-Save as non-Executive Director.
Oaklins' team in the Netherlands identified potential partners, initiated contact and led talks on potential cooperation with a number of parties and advised the buyer in this transaction.
© 2018 Oaklins. All rights reserved. Oaklins is the collective trade name of independent member firms affiliated with Oaklins International Inc. For details of the nature of affiliation, please refer to www.oaklins.com/legal.